When they evaluated it in a validation cohort of 34 patients with MM, 33 (97.1%) achieved the pre-specified CD34+ stem cell targets (6 × 106/kg for patients expected to receive tandem ASCT and 3 × 106/kg for others). The gene discussed is CD34; the disease is Miyoshi myopathy.